Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae-Reference-Cited by-同舟云学术

Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae

Published:2008-02 Issue:6 Volume:26 Page:743-752
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Tobias Joshua,Lebens Michael,Bölin Ingrid,Wiklund Gudrun,Svennerholm Ann-Mari

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference43 articles.

1. Epidemiology of travelers’ diarrhea and relative importance of various pathogens;Black;Rev Infect Dis,1990

2. Enterotoxigenic Escherichia coli (ETEC): epidemiology, microbiology, and clinical features in developing countries;Qadri;Clin Microb Rev,2005

3. Coli surface antigens associated with enterotoxigenic Escherichia coli strains isolated from persons with traveler's diarrhea in Asia;Serichantalergs;J Clin Microbiol,1997

4. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000;Kosek;Bull WHO,2003

5. Colonization factors of human enterotoxigenic Escherichia coli (ETEC);Gaastra;Trends Microbiol,1996

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in oral enterotoxigenic Escherichia coli vaccines;Current Opinion in Immunology;2023-10

2. Use of an ETEC Proteome Microarray to Evaluate Cross-Reactivity of ETVAX® Vaccine-Induced IgG Antibodies in Zambian Children;Vaccines;2023-05-04

3. The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen;Microorganisms;2023-01-30

4. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial;The Lancet Infectious Diseases;2020-02

5. Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development;Frontiers in Microbiology;2018-03-20